DISEASE INDICATIONS: Breast Cancer, Gynaecological Cancer

MANUFACTURER: AstraZeneca AB

USAGE: Oral

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Health Canada

Therapeutic Goods Administration (TGA)

Medsafe (NZ)

Lynparza is a medication that inhibits PARP enzymes, which repair DNA, to treat ovarian, fallopian tube, or primary peritoneal cancer in adults who have undergone more than three chemotherapy treatments, and it promotes cancer cell death.